Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD, page-127

Hopefully one thing we can all agree on is that this was a poorly executed ANN. This company has been hitting everything pretty well since the beginning of the Phase IIA trial a few years ago, but that's been mostly good news. This is the first ANN in a while that was neutral news and they bungled it. Very much the old ANP. The language in the ANN very much made it seem like they were trying to cover something up. In this case, I think the ANN would have been much better received if they just clearly stated what was going on, rather than dance around the facts. The coverup (Diamond's vague ANN) was worse than the crime (the neutral news from the FDA) in this case IMO, and the market punished ANP for it.